| Nov 18 |
Akero a new buy at Citi on liver disease asset
|
| Nov 15 |
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
|
| Nov 13 |
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
|
| Nov 13 |
Akero Therapeutics Advances in MASH Treatment Trials
|
| Nov 8 |
Akero Therapeutics GAAP EPS of -$1.05 misses by $0.11
|
| Nov 8 |
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 2 |
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
|
| Oct 21 |
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
|
| Oct 16 |
Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin
|
| Oct 15 |
Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds
|
